KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Assets Average (2016 - 2025)

Historic Assets Average for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $7.5 billion.

  • Biomarin Pharmaceutical's Assets Average rose 828.33% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 billion, marking a year-over-year increase of 828.33%. This contributed to the annual value of $6.9 billion for FY2024, which is 464.46% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Assets Average stood at $7.5 billion, which was up 828.33% from $7.3 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Assets Average registered a high of $7.5 billion during Q3 2025, and its lowest value of $5.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Assets Average was $6.5 billion (2023), whereas its average is $6.5 billion.
  • Data for Biomarin Pharmaceutical's Assets Average shows a peak YoY increase of 2379.92% (in 2021) and a maximum YoY decrease of 19.88% (in 2021) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Assets Average (Quarter) stood at $6.0 billion in 2021, then rose by 5.48% to $6.3 billion in 2022, then rose by 7.6% to $6.8 billion in 2023, then rose by 1.77% to $6.9 billion in 2024, then rose by 8.89% to $7.5 billion in 2025.
  • Its last three reported values are $7.5 billion in Q3 2025, $7.3 billion for Q2 2025, and $7.1 billion during Q1 2025.